The global sales of central venous catheter is estimated to be worth USD 2,861.0 million in 2024 and anticipated to reach a value of USD 5,436.8 million by 2034. Sales are projected to rise at a CAGR of 6.6% over the forecast period between 2024 and 2034. The revenue generated by peripherally inserted central catheters (PICC) in 2023 was USD 2,694.1 million.
The market for central venous catheters has been witnessing an unexpected boom due to the growing demand from critical care, oncology, and intervention procedures. CVCs have become an indispensable device in the delivery of drugs, fluids, and nutrients into the bloodstream, while the most common application of these catheters is for hemodynamic monitoring or blood sampling. The demand for central venous catheters has seen a rise in different fields of practice like CCUs, amongst others, even in long-term treatments such as chemotherapy and dialysis.
The improvement in the catheter material, infection-resistant coating, and insertion techniques has enabled better patient outcomes with a reduction in complications associated with catheters due to vascular dysfunction or infection.
In addition to the above factors, more healthcare professionals-surgeons, anesthesiologists, and interventional radiologists-are favoring minimally invasive procedures, which further enhances demand for CVCs. They will be set to continue to grow due to the rise of chronic disease and population aging, as they play a very important role in both primary and specialty care.
Global Central Venous Catheter Industry Assessment
| Attributes | Key Insights |
|---|---|
| Historical Size, 2023 | USD 2,694.1 million |
| Estimated Size, 2024 | USD 2,861.0 million |
| Projected Size, 2034 | USD 5,436.8 million |
| Value-based CAGR (2024 to 2034) | 6.6% |
While the tip location devices improved the accuracy and success rate in PICC and CVC insertions, they enhance placing the catheter tips near cardio-arterial and major venous junctions by physicians. Precise positioning of the catheter tip in the lower third of the superior vena cava is essential; otherwise, serious complications due to improper positioning may occur, which includes arrhythmias, precordial discomfort, cardiac tamponade, and valve damage.
This lesser need for chest X-ray confirmation for catheter positioning, therefore, increases the demand for CVCs. Much more accurate tip location devices have contributed to increase the growth for the CVC market. Proper placement of the catheter tip is imperative to avoid CRBSI, thrombosis, and vessel perforation. Accuracy during the procedure is greatly improved by tip location devices, which in turn cuts down on the need for repositioning and repeat procedures.
The global vascular access devices market, within which CVCs are included, has been growing with the rise in the incidence of chronic diseases like cancer, kidney failure, and cardiovascular disorders. This, in turn, has fueled demand for proper and accurate catheter placement. The consequent increasing demand for tip location devices resulting from breakthroughs in imaging, system integration, and user interfaces gives further way to market growth and increased adoption on the part of medical professionals.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The above table presents the expected CAGR for the global central venous catheter market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly lower growth rate of 7.0% in the second half (H2) of the same decade.
| Particular | Value CAGR |
|---|---|
| H1 | 7.3% (2023 to 2033) |
| H2 | 7.0% (2023 to 2033) |
| H1 | 6.6% (2024 to 2034) |
| H2 | 6.1% (2024 to 2034) |
The above table presents the expected CAGR for the global central venous catheter market over several semi-annual periods spanning from 2024 to 2034. In the first half (H1) of the decade from 2023 to 2033, the business is predicted to surge at a CAGR of 7.3%, followed by a slightly lower growth rate of 7.0% in the second half (H2) of the same decade.
Moving into the subsequent period, from H1 2024 to H2 2034, the CAGR is projected to decrease slightly to 6.6% in the first half and decrease moderately at 6.1% in the second half. In the first half (H1) the market witnessed a decrease of 70 BPS while in the second half (H2), the market witnessed a decrease of 90 BPS.
The Central Venous Catheter Market is growing amidst Increasing Number of Diseases with PICC Application
Effective healthcare faces several obstacles due to the rising global prevalence of diseases including cancer, acute infections, and trauma. Healthcare professionals are becoming more likely to employ PICC to provide proper patient care in emergency situations as well as inpatient hospital settings. One of the most prevalent causes for PICC lines is cancer, as patients with this condition frequently need long-term intravenous access and treatment.
The most recent statistics from 2021 by the International Agency for Research on Cancer (IARC) estimates there were 10 million cancer-related deaths, approximately 19.3 million newly diagnosed cancer cases approximately among the global population. Patients receiving haemodialysis for chronic renal diseases, including but not limited to End Stage Renal Disease (ESRD), must have a central venous access catheter (CVC) inserted into a large venous vessel prior to, or will commence after starting haemodialysis.
Sepsis is considered to be an interventional regulatory infection resulting in organ dysfunction or dysfunction of another organ system, and most often minimally requires intravenous broad-spectrum antibiotics administered with a central venous catheter, which can be a peripherally inserted central catheter (PICC) line.
Approximately 30 million people are diagnosed every year with sepsis according to the World Health Organization (WHO). Similarly, patients who cannot sustain appropriate nutritional intake orally may require long-term parenteral nutrition therapy, as in via a PICC line. Malnourishment is the cause of many deaths around the world yearly, for all populations, and stunted 149 million children under 5 years of age due to malnourishment.
Antimicrobial-coated Catheters Introduced by Manufacturers is Creating Opportunities for Central Venous Catheter Industry
The manufacturers of central venous catheters are constantly developing new, superior, and innovative products. These manufacturers have a tremendous opportunity to address the infection potential of vascular access devices and promote patient safety.
Furthermore, from the manufacturer’s perspective, the introduction of antimicrobial-coated central venous catheters provides differentiation and a competitive advantage to catheters in the marketplace. Both infection prevention and patient safety have become a greater higher priority to providers of vascular access devices, making current antimicrobial technology a more appealing proposition as a differentiator.
Central venous catheters are utilized routinely in the treatment of patients, suffering from malignancies in chemotherapy, parenteral nutrition, hemodialysis or critically ill. This population and conditions treated is increasing due to an older population and lifestyle, quality of medical care. The increase in the census of this older population will substantially increase the usage of catheters in practice.
Many complex medical treatment and intervention like central venous catheters are predominately on older adults. When considering the intervention, of treatment, in some small percentage of l-life threatening diseases like cancer, prolonged or continuous intervention or treatment with central venous catheters is warranted.
Higher Costs of Antimicrobial Coated Catheters Limit Adoption and Market Growth of Central Venous Catheter Industry
Central venous catheter manufacturing companies introduce innovative, technically advanced products into the market. These kinds of products create better opportunities for the companies by reducing infections associated with vascular access devices, thereby improving patient safety.
Catheters treated with antimicrobial agents can significantly lower the incidence of CRBSIs. Antimicrobial drugs, such as minocycline, silver, or chlorhexidine, when applied to the catheter's surface, prevent colonizing germs from growing and from infecting others. Antimicrobial-coated catheters should, in theory, improve patient safety, improve clinical outcomes, and save healthcare expenditures related to infection control because to the decreased frequency of CRBSIs they provide.
Therefore, the number of patients that are exposed to treatments using a central venous catheter means a bigger market size and demand. The aging population contributes as a significant force of demand within the market for central venous catheters. Advanced age subjects are very often exposed to complicated medical treatments and interventions that may involve the application of a central venous catheter.
Principal Consultant
The global central venous catheter industry recorded a CAGR of 4.9% during the historical period between 2019 and 2023. The growth of central venous catheter industry was positive as it reached a value of USD 2,694.1 million in 2023 from USD 2,200.6 million in 2019.
Historically, demands for CVCs have shown stable growth in the global market due to increasing numbers of hospitalizations, especially patients suffering from chronic illnesses that involve the spread of cancerous conditions, renal failure, and cardiovascular disorders.
Over the last decade, there has been further development of health infrastructures, increased awareness about infection control, and technological advancement in catheters. The market for Central Vascular Catheters recorded steady growth due, in large part, to increased incidence of life-threatening diseases needing long-term intravenous therapies.
The major two purchasing segments of CVC are hospitals and ambulatory care. This domination was led by North America and Europe because of the highly developed infrastructures of health. The CVC market is very promising, with future growth fueled by continuous technological innovations along with an upsurge in demand for minimally invasive procedures. The vascular access devices also show huge demand due to factors such as increasing elderly population and rising incidence rates of several chronic diseases.
The incorporation of tip location devices and real-time imaging into central venous catheters has enhanced competition in the global CVC market, wherein many manufacturers participate in product innovation, improvement of safety features, and strategic mergers and acquisitions.
Tier 1 companies comprise market leaders with a market revenue of above USD 100 million capturing significant market share of 48.5% in global market. These market leaders are characterized by high production capacity and a wide product portfolio. These market leaders are distinguished by their extensive expertise in manufacturing and a broad geographical reach, underpinned by a robust consumer base. Prominent companies within tier 1 include Medtronic Plc., Becton, Dickinson and Company, Fresenius Medical Care AG & Co. KGaA, B. Braun Melsungen AG among others.
Tier 2 companies include mid-size players with revenue of USD 50 to 100 million having presence in specific regions and highly influencing the local market and holds around 21.2% market share. These are characterized by a strong presence overseas and strong market knowledge.
These market players have good technology and ensure regulatory compliance but may not have advanced technology and wide global reach. Prominent companies in tier 2 include Cook Group, Smiths Medical, Teleflex Incorporated, Integer Holdings Corporation, Vygon S.A., Lepu Medical Technology, Argon Medical Devices, Inc., Merit Medical Systems, Inc., AngioDynamics, Inc. among others.
Finally, Tier 3 companies, such as Biomerics, Medical Components, Inc., KIMAL PLC, Heka s.r.l. among others are essential for the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The section below covers the industry analysis for the central venous catheter market for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Asia Pacific, Europe, and others, is provided. The United States is anticipated to remain at the forefront in North America, with a value share of 94.4% through 2034. In Asia Pacific, South Korea is projected to witness a CAGR of 6.0% by 2034.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| Canada | 5.5% |
| Brazil | 6.0% |
| France | 5.7% |
| Russia | 6.9% |
| Japan | 6.7% |
| South Korea | 6.1% |
| Spain | 6.3% |
USA central venous catheter market is poised to exhibit a CAGR of 6.8% between 2024 and 2034. Currently, it holds the highest share in the North American market, and the trend is expected to continue during the forecast period.
Surgeons and anesthesiologists often use CVCs to deliver vital drugs, blood products, or nutrition directly into the bloodstream. The CVC is an important modality in treating complicated cases that may involve emergency surgery or intensive care, as it allows the administration of large volumes rapidly with precision.
Interventional radiologists use CVCs during minimal invasion procedures for the insertion of ports used in chemotherapy or for long-term medication, among other treatment modes such as dialysis. Most surgeons, anesthesiologists, and interventional radiologists prefer CVC because they have options of single-lumen, double-lumen, or multi-lumen catheters depending on the clinical needs.
East Asia, spearheaded by China currently holds around 51.2% share of the East Asia central venous catheter industry. East Asia’s market is anticipated to grow at a CAGR of 7.5% throughout the forecast period.
Distribution and collaboration arrangements in China also continue to be one of the major drivers of demand in the CVC market. Local distributors and healthcare providers in China come together with partnerships to provide international manufacturers with greater access to the rapidly growing healthcare market. This enables the companies to overcome regulatory hurdles with greater efficiency, builds logistics, and opens up the various hospital networks of China.
Besides, such agreements allow product localization, matching products with Chinese healthcare standards and requirements. In return, the products of CVC are gaining access to various regions within China, particularly in Tier II and III cities. Growing efforts to enhance the healthcare infrastructure and access to these regions are further enticing the demand for CVCs mainly due to the rise in chronic disease cases. Strategic partnerships have thus become the major driving force for product penetration and market share in the changing healthcare landscape of China.
UK is expected to have a strong foothold when it comes to technology innovation. In 2023 the country is projected to account for almost 15.5% of the European central venous catheter market.
The primary factor boosting the growth of the Central Venous Catheter market in the UK is the increase in the number of healthcare services toward home-based and outpatient care approaches. Growing efforts toward a reduction of hospital admissions, along with management for long-term care of patients with chronic diseases like cancer, renal failure, and cardiovascular diseases, have made the application of CVC highly useful. These devices facilitate continuous medication, parenteral nutrition, and dialysis treatments without prolonged hospitalization.
The major factors contributing to the growth of the CVC market in the UK include increasing preference for outpatient care, technological advancements, and favorable government policies for treatment at home. With a greater number of patients being treated out of non-hospital environments, safe and effective CVCs will also see increased demand, thereby acting as one of the key drivers of market growth in the near future.
The section contains information about the leading segments in the industry. By Immunostimulants type, the Glucans segment is estimated to grow at a CAGR of 5.9% throughout 2034.
| Product Type | Peripherally Inserted Central Catheters (PICC) |
|---|---|
| Value Share (2024) | 40.2% |
In 2024, the peripherally inserted central catheters (PICC) segment emerges as the revenue leader, commanding 40.2% of the market share. Several critical factors are responsible for this growing trend of PICC adoptions. One of the major advantages attributed to PICCs is that they carry a lesser risk of complications upon their use compared to the traditional central venous catheters. Infections, pneumothorax, and other related catheter issues are reduced to a minimum, hence making the PICCs safer especially for long-term uses in patients.
Unlike other traditional central venous catheters, which often required surgical procedures or other complex techniques, PICCs are inserted peripherally-usually in the upper arm. This process is less invasive and can be done in various settings, including non-hospital environments, which adds to their convenience and appeal.
One of the major factor contributing factors include cost-effectiveness. Ease of insertion means no surgical intervention and follow-up, thus making the procedure economically viable for long-term intravenous therapy. Other advantageous factors concerning PICCs are that extended-dwell devices can be left in place from weeks to months, which is quite suitable for those patients who are under protracted treatments such as chemotherapy or antibiotic administration.
| End User | Hospitals |
|---|---|
| Value Share (2024) | 61.3% |
The hospitals segment will account for a revenue of over USD 412.2 million in the central venous catheter market by 2024 end. It is also poised to expand at a CAGR of 7.0% across the forecast period.
Hospitals are the primary consumers of the Central Venous Catheter (CVC) market, influenced by multiple factors. They treat the highest volume of patients undergoing life-saving operations complicated by extended needs for a CVC for delivery of medications and fluids in fields such as: surgical operations, chemotherapy, and dialysis, all of which make hospitals the largest user of CVCs. Hospitals are specifically equipped to treat complicated medical conditions such as cancer, cardiovascular diseases, or even kidney failure which may require their prolonged use.
Finally, in accounting for regulatory jurisdictional guidelines related to catheter care and prevention of infections, hospitals also represent the primary users of CVCs in practice.
Substantial investments in the central venous catheter market are increasingly focused on acquisitions and expansion to drive growth and strengthen market presence. Companies are prioritizing the acquisition of innovative technologies and products to enhance their offerings, while also pursuing strategic partnerships to expand their global footprint.
Recent Industry Developments in Central Venous Catheter Market
In terms of product type, the industry is divided into peripherally inserted central catheters (PICC), implanted port, tunneled central venous catheters and non-tunneled central venous catheters.
In terms of design, the industry is segregated into single lumen, double lumen, and multiple lumen.
In terms of Composition, the industry is segregated into polyurethane, Teflon and silicone rubber.
The industry is classified by end user as hospitals, ambulatory surgical centers, specialized clinics and cancer research institutes.
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe and Middle East & Africa have been covered in the report.
The global central venous catheter industry is projected to witness CAGR of 6.2% between 2024 and 2034.
The global central venous catheter industry stood at USD 2,694.1 million in 2023.
The global central venous catheter industry is anticipated to reach USD 5,436.8 million by 2034 end.
China is set to record the highest CAGR of 8.5% in the assessment period.
The key players operating in the global central venous catheter industry include Becton, Dickinson and Company, Teleflex Incorporated, B. Braun Melsungen AG, AngioDynamics, Inc., Medtronic Plc., Smiths Medical (ICU Medical Inc.), Cook Group, Vygon S.A., Argon Medical Devices, Inc., KIMAL PLC, Lepu Medical Technology (Beijing) Co., Ltd. (Comed B.V.), Merit Medical Systems, Inc., Fresenius Medical Care AG & Co. KGaA, Medical Components, Inc., Integer Holdings Corporation, Biomerics, Heka s.r.l.
Explore Healthcare Insights
View Reports
Central Venous Catheter Market
